Artiva's off-the-shelf cell therapy shows 71% response in RA, rivaling CAR-T

Artiva Biotherapeutics Inc. (Nasdaq: ARTV) will present late-breaking data showing its allogeneic NK cell therapy, when combined with rituximab, produced clinical responses comparable to autologous CAR T-cell therapy in 31 patients with rheumatologic diseases. The announcement, made ahead of the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, detailed a 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up.

The data will be presented by Dr. Norman B. Gaylis of Arthritis & Rheumatic Disease Specialties at the EULAR congress in London, scheduled for June 3-6. According to the company's statement, none of the RA patients in the cohort have relapsed or required new immunomodulatory agents, pointing to the durability of the response. Artiva plans to host a webcast for investors on June 8 to discuss the findings.

The results cover a basket of rheumatologic diseases and include a presentation on the first patient with severe Sjögren disease treated with the combination, AB-101 (AlloNK) and rituximab. Further poster presentations will highlight the therapy's ability to achieve deep B-cell depletion, a key mechanism in treating these autoimmune conditions, and a favorable safety profile.

This positions Artiva’s AlloNK®, an "off-the-shelf" therapy derived from healthy donor cells, as a potentially more accessible and scalable alternative to autologous CAR T-cell therapies, which require engineering a patient's own cells. The company plans to initiate a Phase 3 registrational trial for AlloNK in refractory RA in 2026, a significant step toward commercialization.

A Crowded Field

Artiva is not alone in targeting B-cells for autoimmune diseases at the EULAR conference. Cullinan Therapeutics (Nasdaq: CGEM) is also set to present initial clinical data for its T-cell engager, CLN-978, in patients with RA and systemic lupus erythematosus (SLE). Cullinan's therapy, which also aims for B-cell depletion, showed early signals of promising clinical activity, setting the stage for a competitive dynamic at the conference. The broader immunotherapy space includes players like ImmunityBio (Nasdaq: IBRX), which is developing therapies to boost lymphocyte proliferation for cancer treatment, underscoring the intense research and development in cell-based treatments.

The Allogeneic Advantage

The core of Artiva's strategy lies in the allogeneic nature of its AlloNK® platform. Autologous CAR T-cell therapies, while effective, are expensive and logistically complex, involving a multi-week manufacturing process unique to each patient. AlloNK is designed as an off-the-shelf, cryopreserved product that can be administered in an outpatient setting. This could significantly reduce costs and wait times for patients with severe autoimmune diseases who have failed multiple other treatments. Artiva's technology was spun out of a partnership with GC Cell in South Korea, granting Artiva exclusive worldwide rights outside of Asia and Australia. The company has not disclosed its current cash runway in the announcement, a critical metric for clinical-stage biotech firms.

The upcoming presentations and subsequent investor webcast will be closely watched. Strong data could validate Artiva's platform and boost investor confidence ahead of the planned Phase 3 trial.

This article is for informational purposes only and does not constitute investment advice.